Javid Gul, Zargar Showkat Ali, Bhat Khurshid, Khan Bashir Ahmad, Yatoo Ghulam Nabi, Gulzar Ghulam Mohamad, Shah Altaf Hussain, Sodhi Jaswinder Singh, Khan Mushtaq Ahmad, Shoukat Abid, Saif Riyaz U
Department of Gastroenterology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar 190 011, India.
Indian J Gastroenterol. 2013 May;32(3):190-4. doi: 10.1007/s12664-013-0304-7. Epub 2013 Mar 21.
Increasing resistance against Helicobacter pylori has resulted in reduced eradication rates.
This study aims to determine whether eradication rates for H. pylori infection with sequential therapy is better than standard triple therapy.
Patients with endoscopy documented peptic ulcer and H. pylori infection confirmed by histology and rapid urease test.
Patients were randomized into two groups; 134 received standard triple therapy (pantoprazole 40 mg, clarithromycin 500 mg and amoxicillin 1 g each administered twice daily) for 10 days and 138 received sequential regimen (pantoprazole 40 mg plus amoxicillin 1 g twice daily for 5 days followed by 40 mg pantoprazole, 500 mg clarithromycin, and 500 mg tinidazole each administered twice daily for 5 days). Eradication was confirmed by histology and rapid urease test. Compliance and adverse effects were determined by the recovery of empty medicine strips and questioning.
The eradication rates with sequential therapy were significantly greater than with standard therapy on both intention-to-treat analysis (76.0 % vs. 61.9 %, p = 0.005; difference, 14.1 % [95 % CI, 6.5-19 %] and per protocol analysis (84.6 % vs. 67.4 %, p = 0.002; difference, 17.2 % [95 % CI, 8.5-23.5 %]). The incidence of side effects did not differ between the two therapy groups. One patient in standard therapy discontinued treatment due to side effects.
Cultures were not performed. Loss to follow up was 5.2 % in standard therapy and 6.5 % in sequential therapy.
Sequential therapy was significantly more effective than standard therapy for eradicating H. pylori infection in peptic ulcer disease in Asian patients. Side effects were similar.
对幽门螺杆菌的耐药性增加导致根除率降低。
本研究旨在确定序贯疗法治疗幽门螺杆菌感染的根除率是否优于标准三联疗法。
经内镜检查证实患有消化性溃疡且经组织学和快速尿素酶试验确诊为幽门螺杆菌感染的患者。
将患者随机分为两组;134例接受标准三联疗法(泮托拉唑40毫克、克拉霉素500毫克和阿莫西林1克,均每日服用两次),疗程10天;138例接受序贯疗法(泮托拉唑40毫克加阿莫西林1克,每日两次,共5天,随后泮托拉唑40毫克、克拉霉素500毫克和替硝唑500毫克,均每日服用两次,共5天)。通过组织学和快速尿素酶试验确认根除情况。通过回收空药条和询问来确定依从性和不良反应。
在意向性分析中,序贯疗法的根除率显著高于标准疗法(76.0%对61.9%,p = 0.005;差异为14.1%[95%CI,6.5 - 19%]),在符合方案分析中也是如此(84.6%对67.4%,p = 0.002;差异为17.2%[95%CI,8.5 - 23.5%])。两个治疗组的副作用发生率没有差异。标准疗法中有1例患者因副作用停止治疗。
未进行培养。标准疗法的失访率为5.2%,序贯疗法为6.5%。
在亚洲患者的消化性溃疡疾病中,序贯疗法根除幽门螺杆菌感染的效果显著优于标准疗法。副作用相似。